Saturday, March 06, 2004 9:28:15 AM
OT / TFWG - I noted that you said you have background in Pharma. I've bought some shares in the foll Co.:
May I ask you if you are familiar with a Company, named Cytogenix Inc. ? http://www.cytogenix.com/
I was tipped off on this Co. by a retired American scientis who told me that the Co. is close to solveing treatment (not Cure) of Herpes, and that every 4th person on the Globe, suffers from Herpes.
Further, the Co. hv also made successful clinical trials on mice, to treat Sepsis, which is a very big problem in the Hospital sector. They are also working on cancer and dermatitis etc.
If I understand correctly, their approach to Herpes, for example, is to use their technology to suppress the virus' ability to replicate. Further, discussions have pointed out that Co. might also be able to inhibit the production of a protien which allows the Herpes virus to remain invisible to the human immune system - Thus allowing the body to defeat the virus itself.
Furthermore, it is claimed, that with gene silencing there is no side affects, as with antibotics. What CYGX is able to do is to treat without affecting other cells, once the problem is found, not only are they able to stop it, but they are able to keep it from reproducing. "It does what its supposed to do then stops"! And all this there is great need for NOW, since many bacteria is now becoming immune to antibotics.
Would be interesting if I could have a comment from an expert in the biz. Tks.
May I ask you if you are familiar with a Company, named Cytogenix Inc. ? http://www.cytogenix.com/
I was tipped off on this Co. by a retired American scientis who told me that the Co. is close to solveing treatment (not Cure) of Herpes, and that every 4th person on the Globe, suffers from Herpes.
Further, the Co. hv also made successful clinical trials on mice, to treat Sepsis, which is a very big problem in the Hospital sector. They are also working on cancer and dermatitis etc.
If I understand correctly, their approach to Herpes, for example, is to use their technology to suppress the virus' ability to replicate. Further, discussions have pointed out that Co. might also be able to inhibit the production of a protien which allows the Herpes virus to remain invisible to the human immune system - Thus allowing the body to defeat the virus itself.
Furthermore, it is claimed, that with gene silencing there is no side affects, as with antibotics. What CYGX is able to do is to treat without affecting other cells, once the problem is found, not only are they able to stop it, but they are able to keep it from reproducing. "It does what its supposed to do then stops"! And all this there is great need for NOW, since many bacteria is now becoming immune to antibotics.
Would be interesting if I could have a comment from an expert in the biz. Tks.
Recent IDCC News
- InterDigital to Spotlight Sensing Expertise and Innovation at IEEE ICC’26 • GlobeNewswire Inc. • 05/26/2026 08:00:00 AM
- InterDigital Expands IoT Licensing Push With New Fintech Patent Agreement (IDCC) • IH Market News • 05/19/2026 02:46:36 PM
- InterDigital signs license agreement with fintech company • GlobeNewswire Inc. • 05/19/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:12:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:52:23 PM
- Investor Conference Presentations Scheduled as InterDigital (IDCC) Engages Market Through June • IH Market News • 05/05/2026 02:32:32 PM
- InterDigital to Present at Four Upcoming Investor Conferences • GlobeNewswire Inc. • 05/05/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:19:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:17:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:15:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:34:10 PM
- InterDigital Announces Financial Results for First Quarter 2026 • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:11:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 11:00:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:59:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:59:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:58:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:56:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:56:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:55:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:54:42 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 08:30:51 PM
- InterDigital’s NAB Showcase to Spotlight HDR Innovation for Advanced and Ad-Supported Streaming • GlobeNewswire Inc. • 04/16/2026 12:00:00 PM
